肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2012年
10期
663-666
,共4页
郭增清%叶韵斌%余家密%王晓杰%陈明水%陈秀容
郭增清%葉韻斌%餘傢密%王曉傑%陳明水%陳秀容
곽증청%협운빈%여가밀%왕효걸%진명수%진수용
结直肠肿瘤%细胞因子诱导杀伤细胞%药物疗法%过继性细胞免疫治疗
結直腸腫瘤%細胞因子誘導殺傷細胞%藥物療法%過繼性細胞免疫治療
결직장종류%세포인자유도살상세포%약물요법%과계성세포면역치료
Colorectal neoplasms%Cytokine-induced killer cells%Drug therapy%Adoptive cellular immunotherapy
目的 评价细胞因子诱导的杀伤(CIK)细胞联合化疗治疗晚期大肠癌的临床疗效.方法 取外周血50 ml,分离单个核细胞,体外经白细胞介素(IL)-2、干扰素γ(IFN-γ)、抗CD3单抗、IL-1刺激培养8d后获得CIK细胞.CIK细胞联合化疗组、行单纯化疗的同期配对晚期大肠癌组患者各50例,比较近期疗效及生存率,流式细胞术检测回输CIK细胞前后患者免疫学指标,并观察其生活质量及不良反应.结果 CIK细胞治疗前患者外周血中CD3+、CD4+、CD8+和NK细胞比例分别为(54.779±14.228)％、(30.821±11.554)％、(16.676±6.256)％、(18.705±9.347)％,治疗后分别为(65.236±14.901)％、(37.292±8.880)％、(25.229±6.711)％、(22.950±8.933)％,较治疗前均显著提高(P＜0.05).CIK细胞联合化疗组患者生活质量明显改善,不良反应轻微.CIK细胞联合化疗组的疾病控制率(DCR)为64％(32/50),高于单纯化疗组的40％(20/50)(P＜0.05).CIK细胞联合化疗组与单纯化疗组生存率差异无统计学意义(P＞0.05).结论 CIK细胞联合化疗可增强晚期大肠癌患者免疫功能,提高患者生活质量,有较好的临床疗效.
目的 評價細胞因子誘導的殺傷(CIK)細胞聯閤化療治療晚期大腸癌的臨床療效.方法 取外週血50 ml,分離單箇覈細胞,體外經白細胞介素(IL)-2、榦擾素γ(IFN-γ)、抗CD3單抗、IL-1刺激培養8d後穫得CIK細胞.CIK細胞聯閤化療組、行單純化療的同期配對晚期大腸癌組患者各50例,比較近期療效及生存率,流式細胞術檢測迴輸CIK細胞前後患者免疫學指標,併觀察其生活質量及不良反應.結果 CIK細胞治療前患者外週血中CD3+、CD4+、CD8+和NK細胞比例分彆為(54.779±14.228)％、(30.821±11.554)％、(16.676±6.256)％、(18.705±9.347)％,治療後分彆為(65.236±14.901)％、(37.292±8.880)％、(25.229±6.711)％、(22.950±8.933)％,較治療前均顯著提高(P＜0.05).CIK細胞聯閤化療組患者生活質量明顯改善,不良反應輕微.CIK細胞聯閤化療組的疾病控製率(DCR)為64％(32/50),高于單純化療組的40％(20/50)(P＜0.05).CIK細胞聯閤化療組與單純化療組生存率差異無統計學意義(P＞0.05).結論 CIK細胞聯閤化療可增彊晚期大腸癌患者免疫功能,提高患者生活質量,有較好的臨床療效.
목적 평개세포인자유도적살상(CIK)세포연합화료치료만기대장암적림상료효.방법 취외주혈50 ml,분리단개핵세포,체외경백세포개소(IL)-2、간우소γ(IFN-γ)、항CD3단항、IL-1자격배양8d후획득CIK세포.CIK세포연합화료조、행단순화료적동기배대만기대장암조환자각50례,비교근기료효급생존솔,류식세포술검측회수CIK세포전후환자면역학지표,병관찰기생활질량급불량반응.결과 CIK세포치료전환자외주혈중CD3+、CD4+、CD8+화NK세포비례분별위(54.779±14.228)％、(30.821±11.554)％、(16.676±6.256)％、(18.705±9.347)％,치료후분별위(65.236±14.901)％、(37.292±8.880)％、(25.229±6.711)％、(22.950±8.933)％,교치료전균현저제고(P＜0.05).CIK세포연합화료조환자생활질량명현개선,불량반응경미.CIK세포연합화료조적질병공제솔(DCR)위64％(32/50),고우단순화료조적40％(20/50)(P＜0.05).CIK세포연합화료조여단순화료조생존솔차이무통계학의의(P＞0.05).결론 CIK세포연합화료가증강만기대장암환자면역공능,제고환자생활질량,유교호적림상료효.
Objective To evaluate the clinical effects of cytokine-induced killer (CIK) cells combined with chemotherapy on the treatment of patients with advanced colorectal cancer.Methods CIK cells were prepared from 50 ml peripheral blood mononuclear cells by stimulated with IL-2,IFN-γ,anti-CD3 monoclone antibody,IL-1 for 8 d.The clinical effects and survival rate were compared between CIK cells combined with chemotherapy group and the chemotherapy group (50 patients with advanced colorectal cancer for each).T cells and NK cells of patients were tested by FCM before and after CIK cells treatment.The improvement of quality of life and toxicity of this therapy were observed.Results The percentages of CD3+,CD4+,CD8+ T cells and NK cells were (54.779±14.228) ％,(30.821±11.554) ％,(16.676±6.256) ％,(18.705±9.347) ％ before CIK cells transfusion.After transfusion,the percentages were (65.236±14.901) ％,(37.292±8.880) ％,(25.229±6.711) ％,(22.950±8.933) ％,respectively.The percentages were expanded greatly (P ＜ 0.05).The patients quality of life were improved clearly with lower toxicity.The DCR of CIK cells combined with chemotherapy group (64 ％,32/50) was higher than the chemotherapy group (40 ％,20/50) (P ＜ 0.05).The survival rate between two groups had no statistical significance (P ＞ 0.05).Conclusion Administration of CIK cells combined with chemotherapy can enhance immune function in patients with advanced colorectal cancer and improve their quality of life,and get good clinical efficacy.
